Boston Scientific: Q3 Earnings Soar, Time to Buy?
Update: 2025-10-23
Description
Boston Scientific crushed Q3 expectations with 20% revenue growth, driven by strong adoption of WATCHMAN and electrophysiology devices, especially in the US and Asia Pacific. The company raised its outlook, fueled by new product launches and strategic acquisitions, but faces headwinds from tariffs and pricing pressures. Is the stock, now trading above $103, a buy? Investors should weigh growth prospects against ongoing risk factors.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
